Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Plumbs Data's Depths To Differentiate CDK4/6 Inhibitor Verzenio

Executive Summary

Lilly highlighted five prognostic factors at SABCS that may be linked to high Verzenio response. As the third CDK4/6 inhibitor on the US market, the company needs to differentiate its breast cancer drug from Pfizer's Ibrance and Novartis's Kisqali.

Advertisement

Related Content

Keeping Track: Delay (For Celgene), Delay (For Allergan), Goose! (Approval For Lilly)
JUNIPER Disappoints But Lilly Continues With Abemaciclib In Different Combos, Cancers
Can Lilly's Abemaciclib Overcome Third Place Finish In CDK4/6 Race?
Novartis Sets 'Flexible Pricing' For Kisqali To Compete Against Pfizer's Ibrance
Pfizer's Ibrance conquers new breast cancer territory
Pfizer wins early Ibrance approval in breast cancer

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100027

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel